Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 51 to 100 of 332

Guidance and quality standards awaiting development
Title	Type
Budesonide (Jorveza) for maintaining remission of eosinophilic oesophagitis in people 2 years and over [ID6486]	Technology appraisal guidance
Bupivacaine–meloxicam for treating postoperative pain [ID2728]	Technology appraisal guidance
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]	Technology appraisal guidance
Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]	Technology appraisal guidance
CAEL-101 with standard care for untreated amyloid light chain amyloidosis [ID6210]	Technology appraisal guidance
Camizestrant as an add-on to palbociclib and abemaciclib for untreated hormone receptor-positive HER2-negative metastatic breast cancer with an ESR1 mutation [ID6535]	Technology appraisal guidance
Camizestrant with palbociclib for untreated oestrogen receptor-positive HER2-negative metastatic breast cancer after adjuvant endocrine treatment [ID6534]	Technology appraisal guidance
Camlipixant for treating refractory or unexplained chronic cough [TSID12072]	Technology appraisal guidance
Canagliflozin for treating type 2 diabetes in people 10 to 17 years [TSID11888]	Technology appraisal guidance
Carfilzomib in combination for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID12176]	Technology appraisal guidance
Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [TSID10214]	Technology appraisal guidance
Ceralasertib with durvalumab for treating advanced non-small-cell lung cancer after antiPD-L1 treatment and platinum-based chemotherapy [ID6612]	Technology appraisal guidance
Children and young people with disabilities and severe complex needs: integrated health and social care support	Quality standard
Clascoterone for treating acne vulgaris in people 12 years and over [ID6572]	Technology appraisal guidance
Concizumab for preventing bleeding episodes in haemophilia A or haemophilia B [ID5099]	Technology appraisal guidance
Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source [ID1417]	Technology appraisal guidance
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 [TSID11839]	Technology appraisal guidance
Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over [TSID11838]	Technology appraisal guidance
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]	Technology appraisal guidance
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]	Technology appraisal guidance
Datopotamab deruxtecan with durvalumab and carboplatin for untreated TROP2-positive advanced non-small-cell lung cancer without actionable genomic alterations [ID6522]	Technology appraisal guidance
Decitabine–cedazuridine with venetoclax for treating acute myeloid leukaemia when induction chemotherapy is unsuitable [ID6601]	Technology appraisal guidance
Delgocitinib for Chronic Hand Eczema [ID12188]	Technology appraisal guidance
Denosumab biosimilar for Giant cell-rich tumours of bone or Skeletal events in bone malignancies ID12150	Technology appraisal guidance
Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria in people 12 years and over [ID6160]	Technology appraisal guidance
Deucravacitinib for treating active psoriatic arthritis [TSID11981]	Technology appraisal guidance
Deuruxolitinib for treating alopecia areata [ID6597]	Technology appraisal guidance
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery [ID1154]	Technology appraisal guidance
Digital technologies that deliver CBT interventions for insomnia and insomnia symptoms (Disordered sleep)	Health technology evaluation
Diverticular disease	Quality standard
Domvanalimab with zimberelimab for untreated unresectable advanced gastric, gastro-oesophageal junction or oesophageal cancer [ID6606]	Technology appraisal guidance
Dorocubicel for treating haematological cancer when a suitable donor is unavailable for an allogeneic haematopoietic stem cell transplant [ID6521]	Technology appraisal guidance
Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]	Technology appraisal guidance
Dostarlimab with docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6530]	Technology appraisal guidance
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age ID6484	Highly specialised technology
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years [TSID12046]	Technology appraisal guidance
Dulaglutide for treating type 2 diabetes [ID1451]	Technology appraisal guidance
Dupilumab for treating bullous pemphigoid [ID6479]	Technology appraisal guidance
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]	Technology appraisal guidance
Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736]	Technology appraisal guidance
Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]	Technology appraisal guidance
Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]	Technology appraisal guidance
Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]	Technology appraisal guidance
Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID5080]	Technology appraisal guidance
Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]	Technology appraisal guidance
Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6146]	Technology appraisal guidance
Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]	Technology appraisal guidance
Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]	Technology appraisal guidance
Durvalumab with radiotherapy for treating unresected node-negative stage 1 or 2 non-small-cell lung cancer [ID6567]	Technology appraisal guidance
Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]	Technology appraisal guidance

Results per page

10
25
50
All